Skin Disorders News

Lebrikizumab monotherapy was efficacious in improving atopic dermatitis in 80% of patients at 1 year, according to results from two phase 3 trials announced by Eli Lilly and Company.

The FDA has extended the approval of Dupixent to include children aged 6 months to 5 years with moderate to severe atopic dermatitis, Regeneron Pharmaceuticals and Sanofi announced in a press release.

CLEVELAND — Options lessen for patients with chronic urticaria who do not respond to initial antihistamine treatment, according to James Fernandez, MD, PhD, of the department of allergy and immunology at the Cleveland Clinic.

Long-term subcutaneous treatment with a C1 inhibitor decreased the frequency and severity of hereditary angioedema attacks as well as the use of on-demand medications, according to a study published in Allergy and Asthma Proceedings.

The administration of antibiotics before cesarean delivery did not increase the risks for asthma, eczema or other allergic conditions in early childhood, providing further support for their use, according to a study published in The BMJ.

Patients with atopic dermatitis, especially those with more severe forms of the disease, are at increased risk for multiple autoimmune conditions, according to a study published in The Journal of Allergy and Clinical Immunology.

Data published in the American Journal of Clinical Dermatology showed that Opzelura cream was a well-tolerated and effective topical treatment for patients with atopic dermatitis.

Genetic, environmental and lifestyle factors influence the risk for food sensitization and food allergies during the first thousand days of life, according to a literature review published in Annals of Allergy, Asthma & Immunology.

Regular use of bleach baths modestly improved atopic dermatitis severity among most patients with a good safety profile, according to a systematic review and meta-analysis published in Annals of Allergy, Asthma & Immunology.

Patients with chronic spontaneous urticaria demonstrated improved outcomes related to idiopathic angioedema after taking omalizumab, according to a study presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.